United States Health

Dyne Therapeutics (NASDAQ:DYN) announced the appointment of Vikram Karnani to its Board of Directors on December 23, 2025.

Zai Lab Limited (NASDAQ:ZLAB) received marketing authorization from China’s National Medical Products Administration (NMPA) for Cobenfy, a groundbreaking treatment for schizophrenia in adults.

Trinity Biotech (NASDAQ:TRIB) shares are in focus after the diagnostics specialist reported a return to positive adjusted EBITDA and secured a major 9 million-unit order for its flagship HIV screening product.

Invivyd (NASDAQ:IVVD) received U.S. Food and Drug Administration Fast Track designation for VYD2311, an investigational monoclonal antibody designed as a long-acting, intramuscular alternative to traditional vaccines for individuals at high risk of severe COVID-19.

AtaiBeckley (NASDAQ:ATAI) saw its common stock added to the NASDAQ Biotechnology Index (NBI) prior to the market open on Dec. 22, 2025, marking a significant milestone in the company’s evolution as a leader in neuropsychiatric drug development.

Novo Nordisk A/S (NASDAQ:NVO) received U.S. Food and Drug Administration approval on Monday for the first oral version of its blockbuster weight-loss medication Wegovy, setting the stage for a January launch that will bypass traditional insurance hurdles

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) received marketing authorization in Japan for their blockbuster drug Dupixent to treat severe asthma in children aged 6 to 11.

Chimeric Therapeutics (ASX:CHM) has secured $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 clinical trial through the end of Phase 1.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal expansion into the early-stage treatment of breast cancer.

Indivior (NASDAQ:INDV) has announced its inclusion in the S&P SmallCap 600 index, effective December 22, 2025.

The company stated that this milestone aligns its capital markets presence with a sharpened U.S. business profile and supports the growth of SUBLOCADE, its first-in-class long-acting injectable for moderate to severe opioid use disorder.

NeuroSense Therapeutics (NASDAQ:NRSN) reported on Monday the successful completion of a safety analysis for its Phase 2 NST-AD-001 study, a critical step in the company's efforts to repurpose its lead ALS candidate, PrimeC, for the treatment of Alzheimer’s disease.